Masataka Takeshita's research while affiliated with Tokyo-Kita Medical Center and other places

... The quantitative data are expressed as photon units (photons/s). [25][26][27] We also used an orthotopic MM model, in which luciferase-expressing KMS26 cells were engrafted into the bone marrow of NOD/SCID mice via tail-vein injection. All animal studies were approved by the Institutional Animal Ethics Committee and performed in accordance with the Guide for the Care and Use of Lab-oratory Animals formulated by the National Academy of Sciences. ...

... Even in cases of relapse, treatment outcomes have improved with the use of novel agents [3]. However, in situations where novel agents have been exhausted or when the disease rapidly progresses, bortezomib (Velcade), thalidomide, dexamethasone, platinum (cisplatin), Adriamycin (doxorubicin), cyclophosphamide, and etoposide (VTD-PACE) have been frequently utilized, with reported effectiveness [4][5][6][7]. However, in the era of monoclonal antibodies, the outcome of VTD-PACE for patients with relapsed/refractory MM (RRMM) with anti-CD38 antibody resistance or triple-class refractory disease has not been fully evaluated. ...

... Accordingly, G-CSF alone may be an alternative method to collect autologous peripheral blood stem cells for elderly patients. On the other hand, a recent retrospective study (25) suggested that the CY regimen exhibits an anti-myeloma effect; therefore, the selection of mobilization methods should be balanced with regard to efficacy and toxicity, especially in elderly patients. ...

... Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of NHL cases [1][2][3]. Although DLBCL has an aggressive disease course and poor prognosis, its clinical outcome and prognosis have improved since the era of rituximab therapy [1,4]. Over the past 10 years, six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combination chemotherapy (R-CHOP), administered every 3 weeks, have been the current standardof-care for previously untreated patients with DLBCL [5,6]. ...

... Stem cell mobilisation in MM is usually performed using a combination of granulocyte-colony stimulating factor (G-CSF) and cyclophosphamide (CY), or G-CSF alone. The former leads to higher CD34 + cell yields [4][5][6][7][8][9][10][11][12][13], but has been associated, particularly at CY doses ≥3 g/m 2 , with significant morbidity from febrile neutropenia and unplanned hospitalisations [10,11,[14][15][16]. Cytokine only mobilisation is less toxic [17,18] but is associated with a higher chance of mobilisation failure in heavily pre-treated individuals [19,20]. ...

... The overexpression of either fusion gene into Ctrl cells enabled hematopoietic colonies to be serially replated in methylcellulose culture with cytokines ( Figure 5C-E) as demonstrated previously. 42,43 In contrast, Kdm4b deficiency significantly reduced colony-forming activity in successive rounds of plating ( Figure 5D,E; Figure S3A), indicating a cell-intrinsic requirement of Kdm4b for robust clonogenic potential coupled with t(8;21). Supporting the compromised colony-forming properties in Kdm4b deficiency, AE-transduced Kdm4b Δ/Δ colony-forming cells displayed significantly decreased expression of HSCfingerprint genes, concurrently with increased expression of genes associated with differentiated states (monocyte and granulocyte fingerprints) 16 ( Figure 5F). ...

... 22 NEDD9-deficient p210-BCR/ABL transgenic mice show an increased number of granulocytes in peripheral blood, a hyperplasia of myeloid and megakaryocytic cells in the bone marrow and a diffuse myeloid infiltration in the spleen, lung and liver, leading to earlier progression and shorter mouse survival, which support NEDD9 capacity to block chronic myeloid leukaemia (CML) progression. 23 There are few studies on the association of NEDD9 and AML. 24 Herein, as far as known, we for the first time identified and verified that NEDD9 expression, among NEDD family members, was significantly increased in AML. ...

... [38,39] e. Polymerase chain reaction (PCR) test: Specific positive bands are amplified with the specific primers for the fungal 18S transfer ribonucleic acid (tRNA) and ribosomal deoxyribonucleic acid (rDNA). [40,41] ...

... Five of the nine patients received a second transplant, three of which died, and two were alive at 5 and 11 months after the second transplant, respectively [16]. In general, chemotherapy followed by a second allo-HCT from an alternative donor seems to be a preferable choice of treatment, though a second transplant from the same donor was also applied with success [39], and in some cases, donor lymphocyte infusion resulted in a transient response [40]. A more recent review of donor cell-derived leukemia by Wiseman et al. included outcome data available in 58 patients [19]. ...

... EPHB4 has an extracellular region containing an ephrin-binding domain, a cysteine-rich domain and two fibronectin type III repeats, and an intracellular region containing a tyrosine kinase domain, a sterile alpha motif and a PDZ-binding motif [4]. The extracellular region and tyrosine kinase domain represent excellent targets for developing high-affinity antagonistic compounds [5][6][7]. EPHB4 activation can promote cancer growth, migration and metastasis by activating downstream signaling pathways including the RAS/MEK/ERK and EPHB4/RHOA pathways [8,9]. Therefore, EPHB4 is a promising therapeutic target for the development of novel treatment for various types of cancers [10]. ...